27 results on '"Crean M"'
Search Results
2. Lessons learned from people with neurological diseases at the time of COVID‐19: The EFNA‐EAN survey
- Author
-
Bodini, B., Moro, E., Jaarsma, J., Cunningham, E., Sellner, J., Walsh, D., Bassetti, C. L., Beghi, E., Bereczki, D., Burlica, A., Cavallieri, F., Crean, M., Di Liberto, G., Helbok, R., Jenkins, T. M., Macerollo, A., Maia, L. F., Oreja-Guevara, C., Ozturk, S., Rakusa, M., Sauerbier, A., Soffietti, R., Taba, P., Pisani, A., Priori, A., von Oertzen, T. J., and Zedde, M.
- Subjects
medicine.medical_specialty ,Neurology ,Short Communication ,perspective ,Neurological disorder ,Disease ,All Neurologists ,COVID‐19 ,Surveys and Questionnaires ,Pandemic ,medicine ,Disinvestment ,Humans ,people with neurological disease ,survey ,Social isolation ,Disease management (health) ,Psychiatry ,Pandemics ,SARS-CoV-2 ,business.industry ,COVID-19 ,chronic disorders ,medical care ,neurology ,Nervous System Diseases ,medicine.disease ,Clinical trial ,Neurology (clinical) ,medicine.symptom ,business - Abstract
Background and purpose The European Federation of Neurological Associations (EFNA), in partnership with the NeuroCOVID‐19 taskforce of the European Academy of Neurology (EAN), has investigated the impact of the first wave of the COVID‐19 pandemic on individuals with neurological diseases, as well as the hopes and fears of these patients about the post‐pandemic phase. Methods An EFNA‐EAN survey was available online to any person living with a neurological disorder in Europe. It consisted of 18 items concerning the impact of the first wave of the COVID‐19 pandemic on the medical care of people with neurological disorders, and the hopes and fears of these individuals regarding the post‐pandemic phase. Results For 44.4% of the 443 survey participants, the overall care of their neurological disease during the pandemic was inappropriate. This perception was mainly due to significant delays in accessing medical care (25.7%), insufficiently reliable information received about the potential impact of COVID‐19 on their neurological disease (49.6%), and a substantial lack of involvement in their disease management decisions (54.3%). Participants indicated that their major concerns for the post‐pandemic phase were experiencing longer waiting times to see a specialist (24.1%), suffering from social isolation and deteriorating mental well‐being (23.1%), and facing delays in clinical trials with disinvestment in neuroscience research (13.1%). Conclusions Despite the great efforts of health services to cope with the first wave of the COVID‐19 pandemic, individuals with neurological conditions feel they have been left behind. These findings provide invaluable insights for improving the care of patients with neurological disorders in the further course of the COVID‐19 pandemic., For 44.4% of individuals with neurological disorders participating in the survey, the overall care of their neurological disease during the pandemic was inappropriate due to significant delays in accessing medical care, insufficient information about the potential impact of COVID‐19 on their neurological disease, and a lack of involvement in their disease management decisions. Survey participants indicated that their major concerns for the post‐pandemic phase were experiencing longer waiting times to see a specialist, suffering from social isolation and deteriorating mental well‐being, and facing delays in clinical trials. Overall, despite the great efforts of health services to cope with the first wave of the COVID‐19 pandemic, people with neurological disorders feel they have been left behind.
- Published
- 2021
3. The EAN Brain Health Strategy: One Brain, One Life, One Approach
- Author
-
Bassetti, C L A, Endres, M, Sander, A, Crean, M, Subramaniam, S, Carvalho, V, Di Liberto, G, Franco, O H, Pijnenburg, Yolande, Leonardi, M, and Boon, P
- Subjects
610 Medicine & health ,360 Social problems & social services - Abstract
BACKGROUND Brain health is essential for health, well-being productivity and creativity across the entire life. Its definition goes beyond the absence of disease embracing all cognitive, emotional, behavioural and social functions which are necessary to cope with life situations. METHODS The EAN Brain Health Strategy responds to the high and increasing burden of neurological disorders. It aims to develop a non-disease, non-age centred holistic and positive approach ('one brain, one life, one approach') to prevent neurological disorders (e.g., Alzheimer's disease and other dementias, stroke, epilepsy, headache/migraine, Parkinson's disease, multiple sclerosis, sleep disorders, brain cancer) but also to preserve brain health and promote recovery after brain damage. RESULTS The pillars of the EAN Brain Health strategy are: 1) Contribute to a global and international Brain Health approach (together with national and subspecialty societies, other medical societies, WHO, WFN, patients' organizations, industry, and other stakeholders); 2) Supporting the 47 European national societies, healthcare and policymakers in the implementation of integrated and people-centred campaigns; 3) Fostering Research (e.g. on prevention of neurological disorders, determinants and assessments of brain health), 4) Promoting Education of students, neurologists, general practitioners, other medical specialists and health professionals, patients, caregivers, and general public; 5) Raising public awareness of neurological disorders and brain health. CONCLUSIONS By adopting this 'one brain, one life, one approach' strategy in cooperation with partner societies, international organisations, and policymakers, a significant number of neurological disorders may be prevented while enhancing the overall well-being of individuals by maintaining brain health through the life course.
- Published
- 2022
- Full Text
- View/download PDF
4. Problems in the Interpretation of Serological Results of Hepatitis B Testing During an Incident of Hepatitis B Virus Reactivation in a Dialysis Unit
- Author
-
Fitzpatrick, F., Crean, M., Kaminski, G., Connell, J., Thornton, L., Murphy, N., Brennan, A., Walsh, J., Humphreys, H., and Smyth, E.
- Published
- 2007
- Full Text
- View/download PDF
5. European Journal of Neurology / EAN consensus statement for management of patients with neurological diseases during the COVID19 pandemic
- Author
-
von Oertzen, Tim J., Macerollo, A., Leone, M. A., Beghi, E., Crean, M., Oztuk, S., Bassetti, C., Twardzik, A., Berecki, D., Di Liberto, G., Helbok, R., Oreja-Guevara, C., Pisani, A., Sauerbier, A., Sellner, J., Soffietti, R., Zedde, M., Bianchi, E., Bodini, B., Cavallieri, F., Campiglio, L., Maia, L. F., Priori, A., Rakusa, M., and Taba, P.
- Subjects
COVID19 ,neurology ,practice guideline ,education ,human ,chronic disease - Abstract
Background and purpose: The recent SARSCoV2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fastevolving pandemic, evidencebased studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID19. Methods: A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP cochairs rated importance on a fivepoint Likert scale. Results were graded by importance and reported as consensus statements. Results: In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fiftynine statements obtained >70% agreement and were retained. In round three, responses were received from 55 cochairs of 29 SPs. Whilst general recommendations related to prevention of COVID19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy. Conclusion: This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID19 pandemic that provides immediate guidance for neurologists. In this fastevolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges. (VLID)5891876 Version of record
- Published
- 2021
6. Comparative zinc dynamics in Atlanta metropolitan region stream and street runoff
- Author
-
Rose, S., Crean, M., Sheheen, D., and Ghazi, A.
- Published
- 2001
- Full Text
- View/download PDF
7. EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic.
- Author
-
von Oertzen, T. J., Macerollo, A., Leone, M. A., Beghi, E., Crean, M., Oztuk, S., Bassetti, C., Twardzik, A., Bereczki, D., Di Liberto, G., Helbok, R., Oreja‐ Guevara, C., Pisani, A., Sauerbier, A., Sellner, J., Soffietti, R., Zedde, M., Bianchi, E., Bodini, B., and Cavallieri, F.
- Subjects
COVID-19 pandemic ,NEUROLOGICAL disorders ,COMORBIDITY ,COVID-19 ,PANDEMICS - Abstract
Background and purpose: The recent SARS‐CoV‐2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast‐evolving pandemic, evidence‐based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID‐19. Methods: A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co‐chairs rated importance on a five‐point Likert scale. Results were graded by importance and reported as consensus statements. Results: In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty‐nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co‐chairs of 29 SPs. Whilst general recommendations related to prevention of COVID‐19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy. Conclusion: This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID‐19 pandemic that provides immediate guidance for neurologists. In this fast‐evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. DIY Community Action: Neighbourhood Problems and Community Self-help
- Author
-
Crean, M., primary
- Published
- 2009
- Full Text
- View/download PDF
9. Hepatitis B reactivation in an Irish dialysis unit, 2005
- Author
-
Thornton, L, primary, Fitzpatrick, F, additional, de la Harpe, D, additional, Brennan, S, additional, Murphy, N, additional, Connell, J, additional, Humphreys, H, additional, Smyth, E, additional, Walshe, J J, additional, Crean, M, additional, and O’ Flanagan, D, additional
- Published
- 2007
- Full Text
- View/download PDF
10. P1.07 Infection Control Implications of Hepatitis B Testing of Haemodialysis Patients during an Incident of HBV Reactivation in a Dialysis Unit
- Author
-
Fitzpatrick, F., primary, Crean, M., additional, Kaminski, G., additional, Connell, J., additional, Jones, L., additional, Thornton, L., additional, Murphy, N., additional, Brennan, A., additional, Walsh, J., additional, Humphreys, H., additional, and Smyth, E., additional
- Published
- 2006
- Full Text
- View/download PDF
11. Expression of delayed toxicity and lethal mutations in the progeny of human cells surviving exposure to radiation and other environmental mutagens.
- Author
-
Mothersill, C., Crean, M., Lyons, M., Mcsweeney, J., Mooney, R., O'Reilly, J., and Seymour, C. B.
- Subjects
- *
GENETIC mutation , *EFFECT of radiation on cells , *CELL death - Abstract
Purpose: Delayed expression of lethal mutations in the progeny of cells which survived a toxic insult was first shown for ionizing radiation and is one of the signs of induced genomic instability. The effect appears to be related to DNA strand breakage or repair but not to the physical break itself. To investigate this and the relationship of lethal mutations or delayed death to other instability endpoints, cultures of immortal but non-transformed human keratinocytes were exposed to a range of environmental mutagens or cytotoxic compounds with different DNA damaging properties. Methods: Delayed expression of damage was assessed by scoring a number of endpoints in the progeny of cells which survived exposure and underwent at least 15 population doublings. Endpoints included delayed apoptosis, cloning efficiency of cells in 'healthy' colonies and expression of the apoptosis regulatory proteins bcl-2 and BAX. Results: The results clearly linked expression of delayed lethal mutations with substances that induced DNA strand breaks. All these substances are known also to induce oxidative stress. The occurrence of delayed damage required a threshold level of toxicity in the initially exposed population, which was remarkably similar for all the e ffective substances except cadmium. Alkylating agents or microtubule poisons that do not permit repair of DNA damage did not cause any delayed death. Conclusion: It is concluded that delayed cell death may be caused by widespread radical damage to DNA which is either signalled, thereby inducing an apoptotic response, or (mis-)repaired yielding a weak or unstable genome. It is likely that the process may be an important factor in determining the long-term response of populations to 'sublethal' levels of environmental mutagens whose mechanism of action includes DNA strand breakage and repair. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
12. `Uncle Wiggly Wings' and the candy drop.
- Author
-
Crean, M.
- Subjects
- HALVORSEN, Gail, 1920-2022
- Abstract
Relates how United States Air Force pilot Lieutenant Gail Halvorsen airlifted chocolate candy bars to the children of West Berlin, Germany, during the Soviet blockade of 1948. Information about the blockade; How the candy drop operation grew; Support from the United States public.
- Published
- 1992
13. EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic
- Author
-
Von Oertzen, T J, Macerollo, A, Leone, M A, Beghi, E, Crean, M, Oztuk, S, Bassetti, C., Twardzik, A, Bereczki, D, Di Liberto, G, Helbok, R, Oreja-Guevara, C, Pisani, A, Sauerbier, A, Sellner, J, Soffietti, R, Zedde, M, Bianchi, E, Bodini, B, Cavallieri, F, Campiglio, L, Maia, L F, Priori, A, Rakusa, M, Taba, P, Moro, E, and Jenkins, T M
- Subjects
education ,610 Medicine & health ,3. Good health - Abstract
BACKGROUND AND PURPOSE The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19. METHODS A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co-chairs rated importance on a five-point Likert scale. Results were graded by importance and reported as consensus statements. RESULTS In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty-nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co-chairs of 29 SPs. Whilst general recommendations related to prevention of COVID-19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy. CONCLUSION This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID-19 pandemic that provides immediate guidance for neurologists. In this fast-evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges.
14. Pacc - a significant advance in management control
- Author
-
CREAN, M., primary and MULLER, J., additional
- Published
- 1964
- Full Text
- View/download PDF
15. A strategic neurological research agenda for Europe: Towards clinically relevant and patient-centred neurological research priorities.
- Author
-
Boon P, Lescrauwaet E, Aleksovska K, Konti M, Berger T, Leonardi M, Marson T, Kallweit U, Moro E, Toscano A, Rektorova I, Crean M, Sander A, Joyce R, and Bassetti C
- Subjects
- Humans, Global Burden of Disease, Research, Europe epidemiology, Nervous System Diseases epidemiology, Nervous System Diseases therapy, Neurology
- Abstract
Background and Purpose: Neurological disorders constitute a significant portion of the global disease burden, affecting >30% of the world's population. This prevalence poses a substantial threat to global health in the foreseeable future. A lack of awareness regarding this high burden of neurological diseases has led to their underrecognition, underappreciation, and insufficient funding. Establishing a strategic and comprehensive research agenda for brain-related studies is a crucial step towards aligning research objectives among all pertinent stakeholders and fostering greater societal awareness., Methods: A scoping literature review was undertaken by a working group from the European Academy of Neurology (EAN) to identify any existing research agendas relevant to neurology. Additionally, a specialized survey was conducted among all EAN scientific panels, including neurologists and patients, inquiring about their perspectives on the current research priorities and gaps in neurology., Results: The review revealed the absence of a unified, overarching brain research agenda. Existing research agendas predominantly focus on specialized topics within neurology, resulting in an imbalance in the number of agendas across subspecialties. The survey indicated a prioritization of neurological disorders and research gaps., Conclusions: Building upon the findings from the review and survey, key components for a strategic and comprehensive neurological research agenda in Europe were delineated. This research agenda serves as a valuable prioritization tool for neuroscientific researchers, as well as for clinicians, donors, and funding agencies in the field of neurology. It offers essential guidance for creating a roadmap for research and clinical advancement, ultimately leading to heightened awareness and reduced burden of neurological disorders., (© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
- Published
- 2024
- Full Text
- View/download PDF
16. The European Academy of Neurology Brain Health Strategy: One brain, one life, one approach.
- Author
-
Bassetti CLA, Endres M, Sander A, Crean M, Subramaniam S, Carvalho V, Di Liberto G, Franco OH, Pijnenburg Y, Leonardi M, and Boon P
- Subjects
- Brain, Global Health, Humans, Neurologists, Nervous System Diseases therapy, Neurology
- Abstract
Background and Purpose: Brain health is essential for health, well-being, productivity and creativity across the entire life. Its definition goes beyond the absence of disease embracing all cognitive, emotional, behavioural and social functions which are necessary to cope with life situations., Methods: The European Academy of Neurology (EAN) Brain Health Strategy responds to the high and increasing burden of neurological disorders. It aims to develop a non-disease-, non-age-centred holistic and positive approach ('one brain, one life, one approach') to prevent neurological disorders (e.g., Alzheimer's disease and other dementias, stroke, epilepsy, headache/migraine, Parkinson's disease, multiple sclerosis, sleep disorders, brain cancer) but also to preserve brain health and promote recovery after brain damage., Results: The pillars of the EAN Brain Health Strategy are (1) to contribute to a global and international brain health approach (together with national and subspecialty societies, other medical societies, the World Health Organization, the World Federation of Neurology, patients' organizations, industry and other stakeholders); (2) to support the 47 European national neurological societies, healthcare and policymakers in the implementation of integrated and people-centred campaigns; (3) to foster research (e.g., on prevention of neurological disorders, determinants and assessments of brain health); (4) to promote education of students, neurologists, general practitioners, other medical specialists and health professionals, patients, caregivers and the general public; (5) to raise public awareness of neurological disorders and brain health., Conclusions: By adopting this 'one brain, one life, one approach' strategy in cooperation with partner societies, international organizations and policymakers, a significant number of neurological disorders may be prevented whilst the overall well-being of individuals is enhanced by maintaining brain health through the life course., (© 2022 European Academy of Neurology.)
- Published
- 2022
- Full Text
- View/download PDF
17. COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.
- Author
-
Rakusa M, Öztürk S, Moro E, Helbok R, Bassetti CL, Beghi E, Bereczki D, Bodini B, Di Liberto G, Jenkins TM, Macerollo A, Maia LF, Martinelli-Boneschi F, Pisani A, Priori A, Sauerbier A, Soffietti R, Taba P, von Oertzen TJ, Zedde M, Crean M, Burlica A, Cavallieri F, and Sellner J
- Subjects
- Humans, Pandemics, SARS-CoV-2, Vaccination psychology, Post-Acute COVID-19 Syndrome, COVID-19 complications, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Nervous System Diseases, Vaccination Hesitancy
- Abstract
Background and Purpose: Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course., Methods: In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation., Results: The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction., Conclusions: The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals., (© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
- Published
- 2022
- Full Text
- View/download PDF
18. Short- and long-term outcome and predictors in an international cohort of patients with neuro-COVID-19.
- Author
-
Beghi E, Helbok R, Ozturk S, Karadas O, Lisnic V, Grosu O, Kovács T, Dobronyi L, Bereczki D, Cotelli MS, Turla M, Davidescu EI, Popescu BO, Valzania F, Cavallieri F, Ulmer H, Maia LF, Amodt AH, Armon C, Brola W, Victoria G, Riahi A, Krehan I, von Oertzen T, Azab MA, Crean M, Lolich M, Lima MJ, Sellner J, Perneczky J, Jenkins T, Meoni S, Bianchi E, Moro E, and Bassetti CLA
- Subjects
- Adult, Aged, Cohort Studies, Coma, Humans, Intensive Care Units, Retrospective Studies, SARS-CoV-2, COVID-19 complications, Neurology, Stroke epidemiology, Stroke therapy, Stupor
- Abstract
Background and Purpose: Despite the increasing number of reports on the spectrum of neurological manifestations of COVID-19 (neuro-COVID), few studies have assessed short- and long-term outcome of the disease., Methods: This is a cohort study enrolling adult patients with neuro-COVID seen in neurological consultation. Data were collected prospectively or retrospectively in the European Academy of Neurology NEuro-covid ReGistrY ((ENERGY). The outcome at discharge was measured using the modified Rankin Scale and defined as 'stable/improved' if the modified Rankin Scale score was equal to or lower than the pre-morbid score, 'worse' if the score was higher than the pre-morbid score. Status at 6 months was also recorded. Demographic and clinical variables were assessed as predictors of outcome at discharge and 6 months., Results: From July 2020 to March 2021, 971 patients from 19 countries were included. 810 (83.4%) were hospitalized. 432 (53.3%) were discharged with worse functional status. Older age, stupor/coma, stroke and intensive care unit (ICU) admission were predictors of worse outcome at discharge. 132 (16.3%) died in hospital. Older age, cancer, cardiovascular complications, refractory shock, stupor/coma and ICU admission were associated with death. 262 were followed for 6 months. Acute stroke or ataxia, ICU admission and degree of functional impairment at discharge were predictors of worse outcome. 65/221 hospitalized patients (29.4%) and 10/32 non-hospitalized patients (24.4%) experienced persisting neurological symptoms/signs. 10/262 patients (3.8%) developed new neurological complaints during the 6 months of follow-up., Conclusions: Neuro-COVID is a severe disease associated with worse functional status at discharge, particularly in older subjects and those with comorbidities and acute complications of infection., (© 2022 European Academy of Neurology.)
- Published
- 2022
- Full Text
- View/download PDF
19. A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology.
- Author
-
Sellner J, Jenkins TM, von Oertzen TJ, Bassetti CL, Beghi E, Bereczki D, Bodini B, Cavallieri F, Di Liberto G, Helbok R, Macerollo A, Maia LF, Oreja-Guevara C, Özturk S, Rakusa M, Pisani A, Priori A, Sauerbier A, Soffietti R, Taba P, Zedde M, Crean M, Burlica A, Twardzik A, and Moro E
- Subjects
- Humans, Pandemics, SARS-CoV-2, Vaccination, COVID-19, Neurology
- Abstract
Coronavirus disease 2019 (COVID-19), a multi-organ disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to challenge health and care systems around the globe. The pandemic has disrupted acute neurology services and routine patient care and has impacted the clinical course in patients with chronic neurological disease. COVID-19 appears to have exposed inequalities of societies and healthcare systems and had a disproportionate impact on already vulnerable communities. The next challenge will be to set up initiatives to stop disparities in all aspects related to COVID-19. From the medical perspective, there is a need to consider inequalities in prevention, treatment and long-term consequences. Some of the issues of direct relevance to neurologists are summarised. With this appraisal, the European Academy of Neurology NeuroCOVID-19 Task Force intends to raise awareness of the potential impact of COVID-19 on inequalities in healthcare and calls for action to prevent disparity at individual, national and supranational levels., (© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
20. The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19.
- Author
-
Beghi E, Helbok R, Crean M, Chou SH, McNett M, Moro E, and Bassetti C
- Subjects
- Adult, Humans, Pandemics, Registries, SARS-CoV-2, COVID-19, Neurology
- Abstract
The COVID-19 pandemic is a global public health issue. Neurological complications have been reported in up to one-third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. community-based), the accuracy of the diagnostic approach and the interpretation of the patients' complaints. Moreover, after recovering, patients can still experience neurological symptoms. To obtain a more precise picture of the neurological manifestations and outcome of the COVID-19 infection, an international registry (ENERGY) has been created by the European Academy of Neurology in collaboration with European national neurological societies and the Neurocritical Care Society and Research Network. ENERGY can be implemented as a stand-alone instrument for patients with suspected or confirmed COVID-19 and neurological findings or as an addendum to an existing registry not targeting neurological symptoms. Data are also collected to study the impact of neurological symptoms and neurological complications on outcomes. The variables included in the registry have been selected in the interests of most countries, to favour pooling with data from other sources and to facilitate data collection even in resource-poor countries. Included are adults with suspected or confirmed COVID-19 infection, ascertained through neurological consultation, and providing informed consent. Key demographic and clinical findings are collected at registration. Patients are followed up to 12 months in search of incident neurological manifestations. As of 19 August, 254 centres from 69 countries and four continents have made requests to join the study., (© 2020 European Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
21. Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective.
- Author
-
Sellner J, Jenkins TM, von Oertzen TJ, Bassetti CL, Beghi E, Bereczki D, Bodini B, Cavallieri F, Di Liberto G, Helbok R, Macerollo A, Maia LF, Oreja-Guevara C, Özturk S, Rakusa M, Sauerbier A, Soffietti R, Taba P, Pisani A, Priori A, Zedde M, Crean M, Burlica A, Twardzik A, and Moro E
- Subjects
- Humans, Primary Prevention, SARS-CoV-2, Vaccination, COVID-19
- Published
- 2021
- Full Text
- View/download PDF
22. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection.
- Author
-
Moro E, Priori A, Beghi E, Helbok R, Campiglio L, Bassetti CL, Bianchi E, Maia LF, Ozturk S, Cavallieri F, Zedde M, Sellner J, Bereczki D, Rakusa M, Di Liberto G, Sauerbier A, Pisani A, Macerollo A, Soffietti R, Taba P, Crean M, Twardzik A, Oreja-Guevara C, Bodini B, Jenkins TM, and von Oertzen TJ
- Subjects
- Europe, Health Surveys, Humans, Neurology, Anosmia etiology, COVID-19 complications, Headache etiology, Myalgia etiology, Psychomotor Agitation etiology
- Abstract
Background and Purpose: Although the main clinical features of COVID-19 infection are pulmonary, several associated neurological signs, symptoms and diseases are emerging. The incidence and characteristics of neurological complications are unclear. For this reason, the European Academy of Neurology (EAN) core COVID-19 Task Force initiated a survey on neurological symptoms observed in patients with COVID-19 infection., Methods: A 17-question online survey was made available on the EAN website and distributed to EAN members and other worldwide physicians starting on 9 April 2020., Results: By 27 April 2020, proper data were collected from 2343 responders (out of 4199), of whom 82.0% were neurologists, mostly from Europe. Most responders (74.7%) consulted patients with COVID-19 mainly in emergency rooms and in COVID-19 units. The majority (67.0%) had evaluated fewer than 10 patients with neurological manifestations of COVID-19 (neuro COVID-19). The most frequently reported neurological findings were headache (61.9%), myalgia (50.4%), anosmia (49.2%), ageusia (39.8%), impaired consciousness (29.3%) and psychomotor agitation (26.7%). Encephalopathy and acute cerebrovascular disorders were reported at 21.0%. Neurological manifestations were generally interpreted as being possibly related to COVID-19; they were most commonly recognized in patients with multiple general symptoms and occurred at any time during infection., Conclusion: Neurologists are currently and actively involved in the management of neurological issues related to the COVID-19 pandemic. This survey justifies setting up a prospective registry to better capture the prevalence of patients with neuro COVID-19, neurological disease characteristics and the contribution of neurological manifestations to outcome., (© 2020 European Academy of Neurology.)
- Published
- 2020
- Full Text
- View/download PDF
23. Diana Edwards (nee Montgomery).
- Author
-
Crean M
- Subjects
- Female, History, 20th Century, History, 21st Century, Humans, New Zealand, Obstetrics history, Women's Health history, Gynecology history
- Published
- 2014
24. Hugh Cameron Burry.
- Author
-
Crean M
- Subjects
- Australia, History, 20th Century, History, 21st Century, New Zealand, Football history, Rheumatology history, Sports Medicine history
- Published
- 2013
25. The importance of being earnest: following up a low level hepatitis B surface antigen (HBsAg) result.
- Author
-
De Gascun CF, Fraher M, Crean M, Connell J, and Hall WW
- Subjects
- Antiviral Agents therapeutic use, DNA, Viral blood, Female, Hepatitis B virology, Hepatitis B Antibodies therapeutic use, Hepatitis B Vaccines administration & dosage, Hepatitis B Vaccines immunology, Humans, Infant, Newborn, Infectious Disease Transmission, Vertical prevention & control, Pregnancy, Pregnancy Complications, Infectious virology, Young Adult, Hepatitis B diagnosis, Hepatitis B Surface Antigens blood, Pregnancy Complications, Infectious diagnosis
- Published
- 2010
- Full Text
- View/download PDF
26. Use of a fourth generation HIV assay for routine screening--the first year's experience.
- Author
-
Fitzpatrick F, Kaminski G, Jones L, Drudy E, and Crean M
- Subjects
- False Positive Reactions, HIV Antibodies isolation & purification, HIV Core Protein p24 isolation & purification, HIV Infections immunology, Humans, HIV Infections diagnosis, Mass Screening methods
- Published
- 2006
- Full Text
- View/download PDF
27. Direct bonding in orthodontics.
- Author
-
Crean MT and Kavanagh DP
- Subjects
- Dental Prophylaxis, Humans, Dental Bonding methods, Orthodontic Appliances
- Published
- 1984
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.